Leadership Overview
Bharat Serums And Vaccines has 9 executives leading key functions including operations, strategy, and quality.
Driven by a commitment to improving health outcomes, Bharat Serums And Vaccines is dedicated to developing innovative biopharmaceutical products that address critical therapeutic needs and enhance patient lives globally.
Driven by a commitment to improving health outcomes, Bharat Serums And Vaccines is dedicated to developing innovative biopharmaceutical products that address critical therapeutic needs and enhance patient lives globally.
Leadership Roles at Bharat Serums And Vaccines
Sivani Deka - Chief Operating Officer, Business (India)
Sivani Deka, the Chief Operating Officer, Business (India) at Bharat Serums And Vaccines, directs all domestic business operations, ensuring alignment with the company's strategic objectives for growth and market penetration within India. Overseeing sales, marketing, and distribution channels, Sivani Deka drives initiatives to expand product accessibility and enhance customer engagement across key therapeutic areas like women's health and critical care. This leadership role involves optimizing operational efficiency and fostering cross-functional collaboration to achieve robust business performance. By implementing targeted strategies, Sivani Deka ensures the effective delivery of innovative treatments to patients nationwide, directly contributing to the company's mission of improving health and saving lives. The focus remains on strengthening BSV's position as a leading biopharmaceutical provider in the Indian market through meticulous execution and strategic oversight.
Rahul Adakmol - Global Chief Operating Officer, International Operations & Business Development
Rahul Adakmol, the Global Chief Operating Officer, International Operations & Business Development at Bharat Serums And Vaccines, spearheads the expansion and operational management of the company's global footprint. This executive directs international business development strategies, identifying new market opportunities and forging strategic partnerships to extend BSV's reach. Overseeing all international operations, Rahul Adakmol ensures seamless execution of business plans across diverse geographic regions, focusing on regulatory compliance and market-specific adaptations. The role involves driving revenue growth through strategic alliances and market entry initiatives, thereby enhancing the company's global presence. By managing complex international supply chains and distribution networks, Rahul Adakmol guarantees the consistent availability of critical biopharmaceutical products worldwide, reinforcing Bharat Serums And Vaccines' commitment to improving global health outcomes.
Jaby Jacob - Senior President
Jaby Jacob, the Senior President at Bharat Serums And Vaccines, holds significant responsibility for driving key strategic initiatives across the organization. This executive focuses on enhancing operational frameworks and fostering business growth, particularly within the company's core therapeutic segments. Jaby Jacob oversees critical functions that support the company's expansion and market presence, ensuring seamless integration of new strategies and processes. The leadership role involves close coordination with other senior executives to achieve overarching business objectives and maintain BSV's competitive edge. By championing innovation and operational excellence, Jaby Jacob contributes directly to Bharat Serums And Vaccines' mission of delivering life-saving treatments and improving patient outcomes globally.
Anish Shah - President
Anish Shah, the President at Bharat Serums And Vaccines, directs the overall strategic vision and operational execution of the company. This executive leads the organization in its pursuit of innovation and market leadership within the biopharmaceutical sector. Anish Shah oversees critical business functions, ensuring that the company's commitment to developing advanced biological, biotech, and pharmaceutical products is consistently met. The role involves fostering a culture of excellence and driving growth across all divisions, with a particular emphasis on critical therapeutic areas. By guiding strategic planning and resource allocation, Anish Shah ensures Bharat Serums And Vaccines effectively addresses global health challenges and enhances patient quality of life through its innovative treatments.
Anil Damle - Senior President, Corporate Projects & Supply Chain
Anil Damle, the Senior President, Corporate Projects & Supply Chain at Bharat Serums And Vaccines, manages the strategic development and execution of critical corporate initiatives and oversees the entire supply chain network. This executive ensures the efficient and reliable flow of raw materials and finished products, maintaining the integrity and availability of BSV's pharmaceutical offerings. Anil Damle directs complex projects aimed at enhancing operational capabilities and infrastructure, supporting the company's rapid growth and expanding market reach. The leadership role involves optimizing logistics, inventory management, and procurement processes to achieve cost efficiencies and ensure timely delivery. By strengthening the supply chain and driving key corporate projects, Anil Damle directly supports Bharat Serums And Vaccines' mission to improve health outcomes globally.
Sanjeeb Mishra - President, Quality
Sanjeeb Mishra, the President, Quality at Bharat Serums And Vaccines, leads the company's comprehensive quality assurance and control systems. This executive ensures that all products meet stringent regulatory standards and internal quality benchmarks, safeguarding patient safety and product efficacy. Sanjeeb Mishra oversees the implementation and maintenance of robust quality management processes across all operational facets, from research and development to manufacturing and distribution. The role involves driving continuous improvement initiatives to uphold the highest levels of quality and compliance. By championing a culture of quality excellence, Sanjeeb Mishra plays a pivotal role in maintaining Bharat Serums And Vaccines' reputation for reliability and in delivering trusted biopharmaceutical solutions to patients worldwide.
Rudradev Mukherjee - President, International Business
Rudradev Mukherjee, the President, International Business at Bharat Serums And Vaccines, drives the strategic expansion and operational management of the company's global market presence. This executive identifies and capitalizes on international growth opportunities, forging key partnerships and ensuring compliance with diverse regional regulations. Rudradev Mukherjee oversees the development and execution of market-specific strategies, aiming to broaden access to BSV's innovative therapeutic products across continents. The leadership role involves managing international sales, distribution networks, and business development initiatives to achieve sustained global revenue growth. By navigating complex international markets, Rudradev Mukherjee significantly contributes to Bharat Serums And Vaccines' mission of improving health and saving lives on a worldwide scale.
Lakhiram Petwal - President, Operations
Lakhiram Petwal, the President, Operations at Bharat Serums And Vaccines, directs the company's manufacturing and operational activities, ensuring efficient production of high-quality biopharmaceutical products. This executive oversees all aspects of the manufacturing process, from raw material sourcing to final product release, adhering to strict quality and safety standards. Lakhiram Petwal focuses on optimizing production workflows, implementing advanced manufacturing technologies, and driving operational excellence to meet growing market demands. The role involves managing production facilities and ensuring compliance with global regulatory requirements. By maintaining robust operational capabilities, Lakhiram Petwal directly supports Bharat Serums And Vaccines' commitment to delivering innovative treatments that improve patient health and save lives.
Swashraya Shah - Chief Medical Officer
Swashraya Shah, the Chief Medical Officer at Bharat Serums And Vaccines, provides critical medical and scientific leadership, guiding the company's research and development efforts. This executive directs the clinical strategy, ensuring that all product development aligns with the highest medical standards and addresses unmet patient needs in critical therapeutic areas. Swashraya Shah oversees clinical trials, regulatory submissions, and medical affairs, ensuring the efficacy and safety of BSV's innovative treatments. The role involves close collaboration with the scientific team to translate research findings into viable pharmaceutical products. By championing evidence-based medicine and fostering a culture of scientific excellence, Swashraya Shah significantly contributes to Bharat Serums And Vaccines' mission of improving health and saving lives through cutting-edge biopharmaceutical solutions.
Explore Leadership Teams in Manufacturing
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
Founded in 1987, Integrated DNA Technologies, Inc. headquartered in Coralville, Iowa, is the supplier of custom nucleic acids, serving the areas of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. The company develops, manufactures, and markets nucleic acid products for the life sciences industry.
Company Leadership MM
AA
AG
CL
Cresco Labs is a multi-state, vertically integrated cannabis company that controls its cultivation, manufacturing, extraction, and packaging practices. Its facilities are powered by agronomists, manufacturing experts, and state-of-the-art agricultural equipment, all of which drive their commitment to quality, purity, and consistency. Cresco Labs packages, ships and distributes its products nationwide, including locations owned and operated by their team. Cresco Labs is headquartered in Chicago, Illinois.
Company Leadership DD
CR
GB
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Bharat Serums And Vaccines Top Executives and Leadership Team
